Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

Summary

The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.

Timeline

Start

2021-09-21

Primary completion

2023-03-31

Completion

2023-09-13

Publications

• Rousseau C, Heyman MF, Ferrer L, Rauscher A, Morel A, Rusu D, Frenel JS, Taupin M, Vilcot L, Allam N, Robert M, Campone M, Campion L, Kraeber-Bodere F. Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE). Eur J Nucl Med Mol Imaging. 2026 Mar;53(4):2403-2413. doi: 10.1007/s00259-025-07619-y. Epub 2025 Nov 1.

Drugs

Indications